Pfizer’s first-quarter revenue missed analyst estimates as it faces an “uncertain and volatile external environment.” ...

Pfizer maintained its 2025 guidance but noted it does not include any impact of tariffs or trade policy, “which we are unable to predict at this time.” ...

Pfizer expanded its cost-cutting plans and posted first-quarter profit above estimates, despite a decline in sales driven by ...

Pfizer (NYSE:PFE) surged about 3% on Tuesday ... Management reaffirmed its full-year 2025 outlook, noting that the forecast does not currently include any potential impact related to future ...

Pfizer reported weaker first-quarter results on Tuesday, with revenue falling short of Wall Street estimates, but earnings beating expectations. The US drugmaker reaffirmed its full-year 2025 ...

Pfizer stock inched down Tuesday on a mixed first-quarter report. Sales missed, but cost cutting led to strong earnings.

Pfizer ( PFE) reported mixed first quarter earnings Tuesday, as the company struggles to gain investor interest in its ...

Fallon Pfizer reported a dip in profits Tuesday, driven partly by lower sales of Covid-19 therapeutic drug Paxlovid, as it maintained a 2025 forecast that does not include potential tariff effects.

Pfizer on Tuesday expanded its cost-cutting efforts and reported first-quarter profit that topped ... Pfizer did not revise its outlook. The company maintained its full-year 2025 outlook ...

Pfizer reaffirmed its 2025 outlook of $61 to $64 billion in revenue and adjusted earnings per share of $2.80 to $3.